Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-05EMA Authorised: Kisqali (ribociclib succinate) — Novartis Europharm Limited
Authorised marketing status for Kisqali (ribociclib succinate) by Novartis Europharm Limited in the breast neoplasms therapeutic area.
-
EMA approval · 2026-07-20EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH
EMA authorised Enhertu (trastuzumab deruxtecan) for breast neoplasms under conditional approval, with Daiichi Sankyo Europe GmbH as MAH.
-
EMA approval · 2026-06-16EMA Authorised: Kadcyla (trastuzumab emtansine) — Roche Registration GmbH
Kadcyla (trastuzumab emtansine) by Roche Registration GmbH has been authorised for use in the European Union for breast neoplasms.
-
EMA approval · 2026-06-12EMA Authorised: Fulvestrant Mylan (fulvestrant) — Mylan Pharmaceuticals Limited
Fulvestrant Mylan has been authorised in the EU for breast neoplasms.
-
EMA approval · 2026-04-24EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-15FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)
FDA approved a supplemental application for ONTRUZANT (trastuzumab) submitted by Organon LLC. The approval encompasses labeling updates rela…
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
-
FDA approval · 2026-03-26FDA Approved: KADCYLA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for KADCYLA (ado-trastuzumab emtansine) submitted by Genentech, Inc. The approval updates the drug's…
-
EMA approval · 2026-03-25EMA Authorised: Orserdu (elacestrant) — Stemline Therapeutics B.V.
The European Medicines Agency authorised Orserdu (elacestrant) for ER-positive, HER2-negative advanced or metastatic breast cancer; decision…
-
EMA approval · 2026-03-25EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG
Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal c…
-
EMA approval · 2026-03-24EMA Authorised: Kadcyla (trastuzumab emtansine) — Roche Registration GmbH
The European Medicines Agency authorised Kadcyla (trastuzumab emtansine) by Roche Registration GmbH for breast cancer, with decision date 19…
-
EMA approval · 2026-03-19EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
The EMA authorised Lynparza (olaparib) for multiple cancers in the European Union. Indications include ovarian cancer, breast cancer, pancre…
-
FDA approval · 2026-03-16FDA Approved: ERIBULIN MESYLATE — Original Application (XGen Pharmaceuticals DJB, Inc.)
FDA approved the Original Application for ERIBULIN MESYLATE (generic) by XGen Pharmaceuticals DJB, Inc.
-
EMA approval · 2026-02-25EMA Authorised: Verzenios (abemaciclib) — Eli Lilly Nederland B.V.
The EMA authorised Verzenios (abemaciclib) under Eli Lilly Nederland B.V. for use in breast cancer.
-
FDA approval · 2026-02-25FDA Approved: ANASTROZOLE — Supplemental Application (Avet Pharmaceuticals Inc)
FDA approved a supplemental application for Avet Pharmaceuticals' anastrozole tablets (ANDA 206037), formalizing regulatory approval for thi…
-
EMA approval · 2026-02-23EMA Authorised: Inluriyo (imlunestrant tosilate) — Eli Lilly Nederland B.V.
EMA authorised Inluriyo (imlunestrant tosilate) for breast cancer, with Eli Lilly Nederland B.V. as the marketing authorisation holder.
-
EMA approval · 2026-02-23EMA Authorised: Ogivri (trastuzumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Ogivri, a trastuzumab biosimilar from Biosimilar Collaborations Ireland Limited, for gastric cancer and breast cancer.
-
EMA approval · 2026-02-09EMA Authorised: Datroway (datopotamab deruxtecan) — Daiichi Sankyo Europe GmbH
Datroway (datopotamab deruxtecan) has been authorised in the European Union for breast cancer by Daiichi Sankyo Europe GmbH.
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
EMA approval · 2026-02-06EMA Authorised: Tuznue (trastuzumab) — Prestige Biopharma Belgium
The European Medicines Agency authorised Tuznue (trastuzumab) from Prestige Biopharma Belgium for breast cancer indications.
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-28EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.
The EMA authorised Herzuma, a trastuzumab biosimilar from Celltrion Healthcare Hungary Kft, for stomach cancer and breast cancer in the EU.